drugset / Trial / NCT01087203

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

NCT01087203

Phase 2 Terminated 73 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of the investigational drug, tanezumab, in adult patients with painful diabetic peripheral neuropathy.

Timeline

Start
2010-03-30
Primary completion
2010-11-18
Completion
2011-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 20 mg Subcutaneous